Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1995-02-06
2000-03-07
Priebe, Scott D.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 691, 435375, 435455, 536 231, 536 235, 530350, C12Q 168, C07H 2100, C12N 1512, C12N 1585, C07K 14435
Patent
active
060338474
ABSTRACT:
Members of the InK4 (Inhibitors of CDK4) family inhibit the activities of specific cyclin D-dependent kinases (CDK4 and/or CDK6), thereby arresting cell cycle progression in G1 phase and preventing chromosomal DNA replication. Disclosed herein are novel mammalian InK4 family members, having apparent molecular masses of 18,000 and 19,000 daltons, designated "InK4c-p18" and "InK4d-p19," respectively, or simply "p18" and "p19." In particular, the invention provides p19 genes and proteins isolated from murine or human cells and p18 genes and proteins from murine cells. When constitutively expressed in cells, p19 inhibits cyclin D-dependent kinase activity in vivo and induces G1 phase arrest. Materials and methods disclosed herein include (1) nucleic acids that encode p18 or p19; (2) methods for detecting nucleic acids encoding p18 or p19 proteins; (3) methods for producing p18 or p19 proteins using nucleic acids that encode p18 or p19, respectively; (4) purified pl8 or p19 proteins and peptide fragments, oligopeptides, or fusion proteins derived therefrom; (5) methods of inhibiting cells from replicating their chromosomal DNA using purified p18 or p19 proteins or derivatives thereof; (6) antibodies that specifically bind p18 or p19; (7) methods for detecting p18 and p19 proteins; (8) methods of stimulating cell growth by blocking p18 or p19 expression via antisense oligonucleotides; (9) methods of gene therapy using nucleic acids that encode p18 or p19; and (10) methods of making transgenic non-human animals that have alterations in the gene encoding p18 or p19, or in both genes.
REFERENCES:
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5174986 (1992-12-01), Berns
patent: 5185260 (1993-02-01), Crissman et al.
Tseng et al., "Antisense oligonucleotide technology in the development of cancer therapeutics", Cancer Gene Therapy 1(1): 75-71, Mar. 1994.
Brown, "Gene therapy `oversold` by researchers, journalists: NIH advisers cite nearly uniform failure". The Washington Post, pp. AI & AZZ, Dec. 8, 1995.
Coghlan, "Gene dream fades away", New Scientist 2005: 14-15, Nov. 25, 1995.
James, "Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes", Antiviral Chem. Chemother. 2(4): 191-214, 1991.
Monia et al., "antitumor activity of a phosphororthioate antisense oligodeoxyribonucleotide targeted against C-raf kinase", Nature Med. 2(6): 668-675, Jun. 1996.
Gura, "Antisense has growing pains", Science 270: 575-577, Oct. 1995.
Stein et al., "Antisense oligonucleotides as therapeutic agents--is the bullet really magical", Science 261: 1004-1012, Aug. 1993.
Baldin, V., et al., "Cyclin D1 is a Nuclear Protein Required for Cell Cycle Progression in G.sub.1," Genes & Devel. 7:812-821 (May 1993).
Bates, S., et al., "Absence of Cyclin D/cdk Complexes in Cells Lacking Functional Retinoblastoma Protein," Oncogene 9(6):1633-1640 (Jun. 1994).
Dowdy, S.F., et al., "Physical Interaction of the Retinoblastoma Protein with Human D Cyclins," Cell 73(3):499-511 (May 7, 1993).
El-Deiry, W.S., et al., "WAF1, a Potential Mediator of p53 Tumor Suppression," Cell 75(4):817-825 (Nov. 19, 1993).
Ewen, M.E., et al., "Functional Interactions of the Retinoblastoma Protein with Mammalian D-type Cyclins," Cell 73(3):487-497 (May 7, 1993).
Gu, Y., et al., "Inhibition of CDK2 Activity in vivo by an Associated 20K Regulatory Subunit," Nature 366:707-710 (Dec. 16, 1993).
Guan, K.-L., et al., "Growth Suppression by p18, a p16.sup.INK4/MTS1 -and p14.sup.INK4B/MTS2 -Related CDK6 Inhibitor, Correlates with Wild-type pRb Function," Genes & Devel. 8(24):2939-2952 (Dec. 15, 1994).
Hannon, G.J., and Beach, D., "p15.sup.INK4B is a Potential Effector of TGF-.beta.-induced Cell Cycle Arrest," Nature 371:257-261 (Sep. 15, 1994).
Harper, J.W., et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," Cell 75(4):805-816 (Nov. 19, 1993).
Kato, J.-Y., et al., "Direct Binding of Cyclin D to the Retinoblastoma Gene Product (pRb) and pRb Phosphorylation by the Cyclin D-Dependent Kinase CDK4," Genes & Devel. 7(3):331-342 (Mar. 1993).
Lukas, J., et al., "DNA Tumor Virus Oncoproteins and Retinoblastoma Gene Mutations Share the Ability to Relieve the Cell's Requirement for Cyclin D1 Function in G1," J. Cell Biol. 125(3):625-638 (May 1994).
Matsushime, H., et al., "Colony-Stimulating Factor 1 Regulates Novel Cyclins During the G1 Phase of the Cell Cycle," Cell 65(4):701-713 (May 17, 1991).
Matsushime, H., et al., "Identification and Properties of an Atypical Catalytic Subunit (p34.sup.PSK-J3 /cdk4) for Mammalian D Type G1 Cyclins," Cell 71(2):323-334 (Oct. 16, 1992).
Matsushime, H., et al., "D-Type Cyclin-Dependent Kinase Activity in Mammalian Cells," Mol. Cell. Biol. 14(3):2066-2076 (Mar. 1994).
Meyerson, M., and Harlow, E., "Identification of G.sub.1 Kinase Activity for cdk6, a Novel Cyclin D Partner," Mol. Cell. Biol. 14(3):2077-2086 (Mar. 1994).
Nasmyth, K., and Hunt, T., "Dams and Sluices," Nature 366:634-635 (Dec. 16, 1993).
Peters, G., "Stifled by Inhibitions," Nature 371:204-205 (Sep. 15, 1994).
Polyak, K., et al., "p27.sup.Kip1, a Cyclin-Cdk Inhibitor, Links Transforming Growth Factor-.beta. and Contact Inhibition to Cell Cycle Arrest," Genes & Devel. 8(1):9-22 (Jan. 1994).
Polyak, K., et al., "Cloning of p27.sup.Kip1, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals," Cell 78(1):59-66 (Jul. 15, 1994).
Quelle, D.E., et al., "Overexpression of Mouse D-type Cyclins Accelerates G.sub.1 Phase in Rodent Fibroblasts," Genes & Devel. 7(8):1559-1571 (Aug. 1993).
Serrano, M., et al., "A New Regulatory Motif in Cell-Cycle Control Causing Specific Inhibition of Cyclin D/CDK4," Nature 366:704-707 (Dec. 16, 1993).
Sherr, C.J., "Mammalian G.sub.1 Cyclins," Cell 73:1059-1065 (Jun. 18, 1993).
Tam, S.W., et al., "Differential Expression and Regulation of Cyclin D1 Protein in Normal and Tumor Human Cells: Association with Cdk4 is Required for Cyclin D1 Function in G1 Progression," Oncogene 9(9):2663-2674 (Sep. 1994).
Toyoshima, H., and Hunter, T., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell 78(1):67-74 (Jul. 15, 1994).
Xiong, Y., et al., "Subunit Rearrangement of the Cyclin-Dependent Kinases is Associated with Cellular Transformation," Genes & Devel. 7(8):1572-1583 (Aug. 1993).
Xiong, Y., et al., "p21 Is a Universal Inhibitor of Cyclin Kinases," Nature 366:701-704 (Dec. 16, 1993).
Stein, C.A., et al., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review," Cancer Research 48: 2659-2668 (May 15, 1988).
Downing James
Hirai Hiroshi
Okuda Tsukasa
Sherr Charles J.
Priebe Scott D.
St. Jude Children's Research Hospital
LandOfFree
InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-361413